drugset / Trial / NCT00440323

Disturbed Sleep Model Study.

NCT00440323

Phase 1 Completed 52 enrolled GlaxoSmithKline
RandomizedCrossoverTreatment

Summary

Subjects will be screened within 28 days. Each treatment session will consist of 2 PSG nights, study drug administration and noise model is conducted on second night.

Timeline

Start
2007-01-05
Primary completion
2007-07-03
Completion
2007-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SB-649868 Small molecule 10 mg Oral
Subject SB-649868 Small molecule 30 mg Oral
Subject Zolpidem Small molecule 10 mg Oral